Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCODONE HYDROCHLORIDE AND IBUPROFEN vs FENTANYL-62
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Oxycodone is a full mu-opioid receptor agonist, leading to analgesia, euphoria, and sedation. Ibuprofen inhibits cyclooxygenase (COX)-1 and COX-2, reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.
Fentanyl is a synthetic opioid agonist primarily acting on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and respiratory depression.
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate,Off-label: Treatment of chronic pain when other options fail
Anesthesia induction and maintenance,Management of acute pain,Treatment of breakthrough pain in opioid-tolerant patients,Off-label: epidural analgesia, procedural sedation
One tablet containing oxycodone hydrochloride 5 mg and ibuprofen 400 mg orally every 6 hours as needed for pain; maximum 4 tablets per day.
For analgesia: 50-100 mcg IV/IM every 1-2 hours as needed. For anesthesia: 2-50 mcg/kg IV. For PCA: 10-20 mcg IV with 5-10 min lockout. Transdermal: 12-100 mcg/h patch every 72 hours; start at 25 mcg/h in opioid-naive patients.
Oxycodone: 3-5 hours; Ibuprofen: 1.8-2.5 hours. Clinical context: Oxycodone's half-life allows dosing every 4-6 hours; Ibuprofen's shorter half-life supports frequent dosing for sustained anti-inflammatory effect.
3–7 hours (terminal elimination half-life; prolonged in elderly, hepatic impairment, or with continuous infusion due to redistribution).
GFR 30-89 m L/min: No adjustment recommended. GFR 15-29 m L/min: Use with caution; consider reducing dose or extending interval; avoid use in severe renal impairment (GFR <30 m L/min) due to risk of ibuprofen accumulation and nephrotoxicity. GFR <15 m L/min: Not recommended.
GFR 30-60 m L/min: no adjustment for single doses; use with caution for chronic therapy. GFR 15-29 m L/min: consider dose reduction by 25-50% and monitor for CNS toxicity. GFR <15 m L/min: avoid transdermal formulations; reduce IV/oral doses by 50-75% and monitor closely.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of just one dose, especially by children, can be fatal; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity due to ibuprofen.
First trimester: Limited data; opioid use associated with neural tube defects and congenital heart defects in some studies; ibuprofen associated with increased risk of cardiac defects and gastroschisis. Second trimester: Ibuprofen may cause oligohydramnios and premature closure of fetal ductus arteriosus. Third trimester: Prolonged use may cause neonatal opioid withdrawal syndrome; ibuprofen contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and fetal nephrotoxicity.
First trimester: Limited data; no clear evidence of major malformations in humans, but opioid exposure may be associated with neural tube defects in some studies. Second trimester: Risk of miscarriage or fetal growth restriction with prolonged use; no specific teratogenic effects identified. Third trimester: Risk of neonatal opioid withdrawal syndrome (NOWS) if used near term; respiratory depression at birth.
Combination product (oxycodone 5 mg/ibuprofen 400 mg) indicated for acute moderate-to-severe pain; limit duration to ≤7 days due to opioid dependence and GI/renal risks; avoid in patients with aspirin/NSAID allergy, asthma, or severe hepatic/renal impairment; monitor for respiratory depression, hypotension, and signs of bleeding; prescribe naloxone for high-risk patients.
Fentanyl-62 (bupivacaine and fentanyl) is used for epidural analgesia. Monitor for respiratory depression, especially in opioid-naive patients. Fentanyl is lipophilic, providing rapid onset but shorter duration than morphine. Co-administration with bupivacaine allows lower fentanyl doses. Avoid in patients with severe hypotension or hypersensitivity to amide anesthetics.
No interactions on record
No interactions on record
OXYCODONE HYDROCHLORIDE AND IBUPROFEN and FENTANYL-62 are distinct pharmacological agents. OXYCODONE HYDROCHLORIDE AND IBUPROFEN belongs to the Opioid Agonist class and is primarily used for Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequateOff-label: Treatment of chronic pain when other options fail. FENTANYL-62 belongs to the Opioid Agonist class and is primarily used for Anesthesia induction and maintenanceManagement of acute painTreatment of breakthrough pain in opioid-tolerant patientsOff-label: epidural analgesia, procedural sedation. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. OXYCODONE HYDROCHLORIDE AND IBUPROFEN carries a safety status of Category D/X, whereas FENTANYL-62 safety is classified as Category D/X. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Oxycodone is metabolized primarily via CYP3A4 and CYP2D6 to active metabolites (noroxycodone, oxymorphone). Ibuprofen is metabolized via CYP2C9 and CYP2C8 to inactive metabolites.
Hepatic metabolism primarily via CYP3A4 to norfentanyl and other inactive metabolites; also undergoes N-dealkylation and hydroxylation.
Oxycodone: primarily renal (87%) as metabolites, with ~19% unchanged; Ibuprofen: renal (90%) as metabolites, with ~10% unchanged; small biliary/fecal elimination for both.
Renal (primarily as metabolites, <10% unchanged; ~75% total metabolites in urine), fecal (~9% total metabolites).
Oxycodone: ~45% bound to albumin; Ibuprofen: >99% bound to albumin.
~80–85% (primarily to alpha-1-acid glycoprotein, also albumin).
Oxycodone: Vd 2.0-3.0 L/kg (high tissue distribution: CNS, muscle); Ibuprofen: Vd 0.1-0.2 L/kg (limited to plasma and extracellular fluid).
3–6 L/kg (large Vd due to high lipophilicity; distributes extensively to tissues and fat).
Oral: Oxycodone 60-87% (higher with repeated dosing due to saturation of first-pass); Ibuprofen 80-100% (rapidly absorbed).
Transdermal: ~92%; Buccal: ~50%; Intranasal: ~50–70%; Oral: <30% (extensive first-pass metabolism).
Child-Pugh Class A (mild): No adjustment recommended. Child-Pugh Class B (moderate): Use with caution; reduce starting dose of oxycodone by 50% (e.g., half tablet) and monitor; ibuprofen should be avoided or used at lowest effective dose. Child-Pugh Class C (severe): Contraindicated due to risk of hepatic encephalopathy and bleeding.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce starting dose by 50% and titrate slowly. Child-Pugh Class C: avoid use or reduce dose by 75% with extended dosing intervals; monitor for respiratory depression.
Not approved in children <18 years of age. For weight-based dosing in adolescents (≥18 years): same as adult based on oxycodone component 0.05-0.15 mg/kg/dose (max 5 mg) and ibuprofen 5-10 mg/kg/dose (max 400 mg) every 6 hours as needed; not to exceed 4 doses per day.
For procedural sedation: 0.5-2 mcg/kg IV/IM; for analgesia: 0.5-1 mcg/kg IV every 1-2 hours. For anesthesia: 2-5 mcg/kg IV for induction; maintenance 0.5-2 mcg/kg/h IV infusion. Transdermal not recommended for opioid-naive children.
Start at lowest effective dose (one-half tablet every 6 hours) due to increased sensitivity to opioids (respiratory depression, constipation) and NSAID-related GI/renal risks; monitor renal function and for cognitive impairment; maximum 4 tablets per day.
Reduce initial dose by 50-75% due to increased sensitivity; titrate slowly. Avoid transdermal patches in frail elderly; use lowest effective dose. Monitor for respiratory depression and constipation. PCA may require lower bolus doses (5-10 mcg) and longer lockout intervals.
Risk of respiratory depression, particularly in non-opioid-tolerant patients; risk of abuse, addiction, and diversion; concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Respiratory depression; addiction potential; interactions with CNS depressants; hepatic impairment; renal toxicity; gastrointestinal bleeding; cardiovascular thrombotic events; adrenal insufficiency; use in elderly; use in pregnancy; breastfeeding.
Respiratory depression, risk of serotonin syndrome with serotonergic drugs, adrenal insufficiency, hypotension, bradycardia, seizures, serotonin syndrome, severe hypotension, and risk of misuse/abuse. Caution in patients with COPD, sleep apnea, head injury, increased intracranial pressure, biliary tract disease, and elderly/debilitated patients.
Significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; hypersensitivity to oxycodone, ibuprofen, or any component; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; in the setting of coronary artery bypass graft (CABG) surgery.
Hypersensitivity to fentanyl or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; suspected or known GI obstruction; concurrent use with MAOIs or within 14 days of discontinuation; non-opioid-tolerant patients for transmucosal immediate-release formulations.
Take with food or milk to reduce GI upset. Avoid grapefruit and grapefruit juice (may increase oxycodone levels and risk of adverse effects). Limit alcohol intake due to additive CNS depression and increased GI bleeding risk.
No food interactions are reported for epidural fentanyl. However, avoid grapefruit juice as it may affect fentanyl metabolism.
Oxycodone excreted in breast milk; M/P ratio approximately 1.1. Ibuprofen excreted in low levels (M/P <0.01). American Academy of Pediatrics considers both compatible with breastfeeding; however, monitor infant for sedation, respiratory depression, and poor feeding due to oxycodone.
Fentanyl is excreted into breast milk in low concentrations; the M/P ratio is approximately 0.4. Use with caution due to potential for infant sedation and respiratory depression; lowest effective dose for shortest duration. Risk of withdrawal in breastfed infants if maternal use is prolonged.
No established dose adjustments for pregnancy; however, increased renal clearance and volume of distribution in pregnancy may require dose increases for adequate analgesia. Avoid supratherapeutic ibuprofen doses; limit to lowest effective dose and shortest duration. Third trimester: avoid ibuprofen entirely.
Increased clearance and volume of distribution in pregnancy may require higher doses or more frequent administration to achieve analgesic effect; titrate to effect, monitor for respiratory depression. No fixed dose adjustment; individualize based on pain severity and response.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not drive or operate machinery until you know how this medication affects you.,This drug contains both an opioid and an NSAID; risk of addiction, respiratory depression, and GI bleeding.,Do not take with other NSAIDs (e.g., ibuprofen, naproxen) or acetaminophen-containing products without medical advice.,Swallow tablets whole; do not crush, chew, or dissolve (may cause rapid release and overdose).,Common side effects: constipation, nausea, dizziness, drowsiness; increase fluids and fiber to prevent constipation.,Seek emergency help if you experience trouble breathing, chest pain, severe dizziness, black/tarry stools, or signs of allergic reaction.,Keep out of reach of children and dispose of unused medication via drug take-back program.,Inform all healthcare providers that you are taking this medication before any surgery or procedure.
Report any difficulty breathing or chest tightness immediately.,Do not drive or operate heavy machinery while receiving this medication.,Avoid alcohol and other CNS depressants.,Inform your doctor of all medications you are taking, especially other pain relievers or sleep aids.,This medication is for hospital use only; do not share with others.